CA 103
Alternative Names: CA-103; CA-103TLatest Information Update: 28 Aug 2023
At a glance
- Originator Curigin
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Androgen receptor antagonists; MTOR protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Benign prostatic hyperplasia; Prostate cancer
Most Recent Events
- 23 Jun 2023 Early research in Benign prostatic hyperplasia in South Korea (IV) (Curigin pipeline, June 2023)
- 23 Jun 2023 Early research in Prostate cancer in South Korea (IV) (Curigin pipeline, June 2023)
- 04 Aug 2022 Curigin has patent protection for CA 103 entitled "Nucleic acid simultaneously inhibiting expression of AR gene and mTOR gene" in Australia, Japan and the US